Akman Canan, Kırılmaz Bahadır, Balcı Serdal, Aksit Ercan, Yurtseven Ersan, Duygu Ali
Emergency Department, Canakkale Onsekiz Mart University Faculty of Medicine, Canakkale, TUR.
Cardiology Department, Canakkale Onsekiz Mart University Faculty of Medicine, Canakkale, TUR.
Cureus. 2021 Jan 28;13(1):e12963. doi: 10.7759/cureus.12963.
Atrial fibrillation (AF) is a rhythm disorder observed mostly amongst adults. AF has been regarded as one of the most important medical problems because it leads to thromboembolism and paralysis risks. Although warfarin has been used in the past to cope with this health problem, new oral anticoagulant medicines have replaced it in the last few years. The new oral anticoagulants, namely, dabigatran etexilate, rivaroxaban, and apixaban, are currently being used in daily clinical practice and treatment guidelines. Since AF patients are supposed to receive long-term oral anticoagulant therapy, it is extremely important to provide them with accurate information and appropriate training regarding the treatment to decrease oncoming complications. This is a prospective study involving 168 patients who were admitted to the emergency department with AF and who were using oral anticoagulants. Findings indicate a lack of awareness in the patients regarding the effects and side effects of the drugs they take despite having been informed by the prescribing physician. We believe that informed action by patients with regard to the oral anticoagulants and their side effects will have an impact on the reduction in hospitalization observed. It will also make a substantial contribution to the quality of life of AF patients and to their use of medical services.
心房颤动（AF）是一种主要在成年人中观察到的节律紊乱。AF被视为最重要的医学问题之一，因为它会导致血栓栓塞和瘫痪风险。尽管过去曾使用华法林来应对这一健康问题，但在过去几年中，新型口服抗凝药物已将其取代。新型口服抗凝剂，即达比加群酯、利伐沙班和阿哌沙班，目前正在日常临床实践和治疗指南中使用。由于房颤患者需要接受长期口服抗凝治疗，因此为他们提供有关治疗的准确信息和适当培训以减少即将出现的并发症极为重要。这是一项前瞻性研究，涉及168名因房颤入院并正在使用口服抗凝剂的患者。研究结果表明，尽管开处方的医生已告知患者，但患者对所服用药物的效果和副作用仍缺乏认识。我们认为，患者对口服抗凝剂及其副作用的明智行动将对观察到的住院率降低产生影响。这也将对房颤患者的生活质量及其医疗服务的使用做出重大贡献。
